OBJECTIVE: Common single nucleotide polymorphisms in the SORL1 gene have been associated with late onset Alzheimer disease (LOAD), but causal variants have not been fully characterized nor has the mechanism been established. The study was undertaken to identify functional SORL1 mutations in patients with LOAD. METHODS: This was a family- and cohort-based genetic association study. Caribbean Hispanics with familial and sporadic LOAD and similarly aged controls were recruited from the United States and the Dominican Republic, and patients with sporadic disease of Northern European origin were recruited from Canada. Prioritized coding variants in SORL1 were detected by targeted resequencing and validated by genotyping in additional family members and unrelated healthy controls. Variants transfected into human embryonic kidney 293 cell lines were tested for Aβ40 and Aβ42 secretion, and the amount of the amyloid precursor protein (APP) secreted at the cell surface was determined. RESULTS: Seventeen coding exonic variants were significantly associated with disease. Two rare variants (rs117260922-E270K and rs143571823-T947M) with minor allele frequency (MAF) < 1% and 1 common variant (rs2298813-A528T) with MAF = 14.9% segregated within families and were deemed deleterious to the coding protein. Transfected cell lines showed increased Aβ40 and Aβ42 secretion for the rare variants (E270K and T947M) and increased Aβ42 secretion for the common variant (A528T). All mutants increased the amount of APP at the cell surface, although in slightly different ways, thereby failing to direct full-length APP into the retromer-recycling endosome pathway. INTERPRETATION: Common and rare variants in SORL1 elevate the risk of LOAD by directly affecting APP processing, which in turn can result in increased Aβ40 and Aβ42 secretion.
OBJECTIVE: Common single nucleotide polymorphisms in the SORL1 gene have been associated with late onset Alzheimer disease (LOAD), but causal variants have not been fully characterized nor has the mechanism been established. The study was undertaken to identify functional SORL1 mutations in patients with LOAD. METHODS: This was a family- and cohort-based genetic association study. Caribbean Hispanics with familial and sporadic LOAD and similarly aged controls were recruited from the United States and the Dominican Republic, and patients with sporadic disease of Northern European origin were recruited from Canada. Prioritized coding variants in SORL1 were detected by targeted resequencing and validated by genotyping in additional family members and unrelated healthy controls. Variants transfected into human embryonic kidney 293 cell lines were tested for Aβ40 and Aβ42 secretion, and the amount of the amyloid precursor protein (APP) secreted at the cell surface was determined. RESULTS: Seventeen coding exonic variants were significantly associated with disease. Two rare variants (rs117260922-E270K and rs143571823-T947M) with minor allele frequency (MAF) < 1% and 1 common variant (rs2298813-A528T) with MAF = 14.9% segregated within families and were deemed deleterious to the coding protein. Transfected cell lines showed increased Aβ40 and Aβ42 secretion for the rare variants (E270K and T947M) and increased Aβ42 secretion for the common variant (A528T). All mutants increased the amount of APP at the cell surface, although in slightly different ways, thereby failing to direct full-length APP into the retromer-recycling endosome pathway. INTERPRETATION: Common and rare variants in SORL1 elevate the risk of LOAD by directly affecting APP processing, which in turn can result in increased Aβ40 and Aβ42 secretion.
Authors: C Pottier; D Hannequin; S Coutant; A Rovelet-Lecrux; D Wallon; S Rousseau; S Legallic; C Paquet; S Bombois; J Pariente; C Thomas-Anterion; A Michon; B Croisile; F Etcharry-Bouyx; C Berr; J-F Dartigues; P Amouyel; H Dauchel; C Boutoleau-Bretonnière; C Thauvin; T Frebourg; J-C Lambert; D Campion Journal: Mol Psychiatry Date: 2012-04-03 Impact factor: 15.992
Authors: Yan Meng; Joseph H Lee; Rong Cheng; Peter St George-Hyslop; Richard Mayeux; Lindsay A Farrer Journal: Neuroreport Date: 2007-11-19 Impact factor: 1.837
Authors: Joseph H Lee; Rong Cheng; Nicole Schupf; Jennifer Manly; Rafael Lantigua; Yaakov Stern; Ekaterina Rogaeva; Yosuke Wakutani; Lindsay Farrer; Peter St George-Hyslop; Richard Mayeux Journal: Arch Neurol Date: 2007-04
Authors: G Nicolas; C Charbonnier; D Wallon; O Quenez; C Bellenguez; B Grenier-Boley; S Rousseau; A-C Richard; A Rovelet-Lecrux; K Le Guennec; D Bacq; J-G Garnier; R Olaso; A Boland; V Meyer; J-F Deleuze; P Amouyel; H M Munter; G Bourque; M Lathrop; T Frebourg; R Redon; L Letenneur; J-F Dartigues; E Génin; J-C Lambert; D Hannequin; D Campion Journal: Mol Psychiatry Date: 2015-08-25 Impact factor: 15.992
Authors: Daniel Felsky; Jishu Xu; Lori B Chibnik; Julie A Schneider; Jo Knight; James L Kennedy; David A Bennett; Philip L De Jager; Aristotle N Voineskos Journal: Alzheimers Dement Date: 2017-03-17 Impact factor: 21.566
Authors: Maria Victoria Fernández; Kathleen Black; David Carrell; Ben Saef; John Budde; Yuetiva Deming; Bill Howells; Jorge L Del-Aguila; Shengmei Ma; Catherine Bi; Joanne Norton; Rachel Chasse; John Morris; Alison Goate; Carlos Cruchaga Journal: Eur J Hum Genet Date: 2016-09-21 Impact factor: 4.246
Authors: Michael W Lutz; Donna Crenshaw; Kathleen A Welsh-Bohmer; Daniel K Burns; Allen D Roses Journal: Curr Neurol Neurosci Rep Date: 2016-05 Impact factor: 5.081
Authors: Chris Gaiteri; Sara Mostafavi; Christopher J Honey; Philip L De Jager; David A Bennett Journal: Nat Rev Neurol Date: 2016-06-10 Impact factor: 42.937